drugset / Trial / NCT00768521

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

NCT00768521

Phase 1 Completed 20 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindTreatment

Summary

This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.

Timeline

Start
2008-09-03
Primary completion
2009-01-19
Completion
2009-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule 4 mg

Indications